M2D2 resident company LivOnyx named a 2019 winner in MLSC MassNextGen Initiative

Lt. Gov. Karyn Polito (far left), LivOnyx President/Co-Founder Carmela Mascio (second from left), and MLSC President Travis McCready (third from right) at the MassNextGen winners announcement event on June 19.

We’re thrilled to spread the word that one of our innovative resident companies, LivOnyx, has been named one of five 2019 winners in the Massachusetts Life Sciences Center (MSLC) Massachusetts Next Generation Initiative. LivOnyx will receive $87,500 in funding, as well as access for a year to a network of executive coaches.  

Continue reading

New EZ BAA Portal Makes BARDA DRIVe Submissions Easier, Speeds Grant Awards.

The new BARDA DRIVe online portal speeds the awarding of grants to health security innovators.

The BARDA DRIVe team is pleased to announce that the new, easy-to-use EZ BAA online Portal is now live as of April 23, 2019. This Portal will replace the existing PDF-based process, helping to improve the user experience, data integrity, and data security. The system will also streamline internal processes, helping DRIVe’s program teams continue to make awards in as few as 30 days.

Continue reading

A Passage FROM India: Chennai-based startups compete in 2019 $200K Challenge

Team India at the 2019 M2D2 $200K Challenge Pitch-Off

With support from the Deshpande Foundation, three finalist startups from an incubator in Chennai, India were able to pitch their life sciences innovations in Lowell on March 27.  Not only did they compete, but they were also able to immerse themselves first-hand in the burgeoning biotech ecosystem that’s making Boston and environs the talk of the innovation economy.

Continue reading

Meet a 2019 M2D2 Challenge Finalist: Dynocardia

Mohan Thanikachalam, CEO of Dynocardia

Dynocardia is 1 of 19 finalists chosen to pitch at the $200K Challenge Pitch-Off last Wednesday. Dynocardia’s ViTrack™ is the first-of-its-kind, standalone, cuff-less, wearable device for continuous non-invasive blood pressure monitoring.

Mohan Thanikachalam, CEO of Dynocardia, offers us an exclusive inside look behind the development of the ViTrackTM!

Read more

Meet a 2019 M2D2 Challenge Finalist: Buzzark Simulations

Buzzark Logo

Top Row, Left to Right: Ragul Puhazhendi, Suha Sudharsanan, and Shiva Prakash of BuzzArk; Bottom Row, Left to Right: Vasanth Raghava, Prof S P Thyagarajan, Dr. T Mohanapriya, and Dr. Ramesh Sadasivan of BuzzArk

 

 

 

BuzzArk Simulations, chosen for their development of a VR simulation for natural orifice surgery procedures, is 1 of 20 MedTech startup finalists in the 8th annual M2D2 $200K Challenge.

Ragul Puhazhendi, Founder of Buzzark, offers us an exclusive inside look at the ups and downs behind the development of their simulation technology.

Continue reading

Meet a 2019 M2D2 Challenge Finalist: UroMonitor

Margot Damaser, Full Staff and Professor at the Department of Biomedical Engineering for The Cleveland Clinic

Margot Damaser, Full Staff and Professor at the Department of Biomedical Engineering for The Cleveland Clinic

 

 

The UroMonitor, a device to simplify and improve the diagnosis and treatment of stress urinary incontinence, was chosen as 1 of 20 finalists in the 8th annual M2D2 $200K Challenge. 

Margot Damaser of Cleveland Clinic leads a team in the development of the UroMonitor. In this article, Margot offers some insight into the background of the innovative device and what it’s taken her team to get it this far!

Continue reading

Meet a 2019 M2D2 Challenge Finalist: Medisim VR

Medisim VR Logo

From left to right, Sabarish RC, Dr. Adith Chinnaswami, and Jeno Manickam of Medisim VR.

From left to right, Sabarish RC, Dr. Adith Chinnaswami, and Jeno Manickam of MediSim VR.

 

 

MediSim VR, one of 21 MedTech startup finalists in the 8th annual M2D2 $200K Challenge, was chosen to compete for their development of a Haptic enabled VR (virtual reality) surgery simulator.

Co-founder, Dr. Adith Chinnaswami, offers an exclusive inside look about this team’s innovation, background, and future plans.

Continue reading